Efficacy Study of Prucalopride to Treat Chronic Intestinal Pseudo-Obstruction (CIP)
|ClinicalTrials.gov Identifier: NCT00793247|
Recruitment Status : Completed
First Posted : November 19, 2008
Last Update Posted : November 19, 2008
|Condition or disease||Intervention/treatment||Phase|
|Chronic Intestinal Pseudo-Obstruction||Drug: PRU-PLA-PRU-PLA Drug: PLA-PRU-PLA-PRU Drug: PLA-PRU-PRU-PLA Drug: PRU-PLA-PLA-PRU||Phase 2|
This phase II, double-blind, placebo-controlled, two-treatment four periods cross-over trial investigated the clinical safety, tolerability and the efficacy of R093877 (prucalopride) in improving the symptoms associated with chronic intestinal pseudo-obstruction (CIP) in subjects with CIP.
Subjects were treated for 4 periods of 12 weeks each with either R093877 2 mg (2 periods) or placebo (2 periods). In each of the first and second 6 month period, there was a placebo (PLA) and an active drug (PRU) treatment period. There were no wash-out periods. In total,7 subjects were randomized; 2 were assigned to the PLA-PRU-PLA-PRU, 2 to the PRUPLA-PRU-PLA, 2 to the PLA-PRU-PRU-PLA, and 1 to the PRU-PLA-PLA-PRU sequence group. Subjects were allowed to use up to 4 mg of prucalopride per day if the 2 mg dose seemed to be insufficient. Two subjects used an average of 3 mg of prucalopride per day during the active drug periods.
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||A Double-Blind, Placebo-Controlled, Cross-Over, Multiple (n=1) Trial to Evaluate the Effects of R093877 in Patients With Chronic Intestinal Pseudo-Obstruction (CIP).|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00793247
|Northwick Park Hospital|
|London, United Kingdom|